Table Legends
Table 1 Nitazoxanide input parameters for the PBPK model
Table 2 Tizoxanide validation against observed data for various
single oral doses in the fasted state
Table 3 Tizoxanide validation against observed data for various
single and multiple oral doses when given with food
Table S1 Legend
Table S1 Nitazoxanide 50% and 90 % effective concentrations
against various influenza virus strains
Figure S1 Legend
Figure S1 Comparison of simulated and observed plasma
concentration–time curve of tizoxanide (TIZ) at fasted state.
(a ) 500 mg, (b ) 1000 mg, (c ) 2000 mg,
(d ) 3000 mg and (e ) 4000 mg.
Figure S2 Legend
Figure S2 Comparison of simulated and observed plasma
concentration–time curve of tizoxanide (TIZ) for single and multiple
dosing regimen (where available) at fed state. (a ) 500 mg,
(b ) 1000 mg, (c ) 2000 mg, (d ) 3000 mg and
(e ) 4000 mg
Figure S3 Legend
Figure S3 Predicted plasma and lung concentrations for optimal
doses during fasted state at different regimens reaching steady state –
(a ) 2900 mg BID, (b ) 1600 mg TID and (c ) 1200
mg QID. TIZ – tizoxanide, SD – standard deviation, solid red line
indicates clinical Cmax of 1 g single dose at fasted
state [29], solid green line represents clinical
Cmax of 500 mg single dose [55] at fasted state and
the dotted red line represents the EC90 of nitazoxanide
for SARS-CoV-2 [44].